Today Endocyte, Inc. (ECYT) Stock Reaches Yearly Low

Xavier Trudeau
Juin 3, 2017

The current share price indicates that stock is -34.22% away from its one year high and is moving 37.88% ahead of its 52-week low. Endocyte had 3 analyst reports since August 5, 2015 according to SRatingsIntel. Vanguard Group Inc. now owns 1,629,836 shares of the biopharmaceutical company's stock worth $4,189,000 after buying an additional 143,497 shares during the last quarter. (NASDAQ:ECYT) on Wednesday, August 5 with "Outperform" rating. The rating was initiated by Credit Suisse with "Outperform" on Thursday, January 21.

The Company's Board of Directors committed to this course of action on May 23, 2017, and the Company informed affected employees on June 2, 2017. The Company's geographic divisions include North America, Asia Pacific (AP), Europe, Middle East and Africa (EMEA), and Latin America (LA). It now has negative earnings. These divisions sell and service financial self-service (FSS), retail solutions and security systems.

About 2.82M shares traded or 492.49% up from the average. Endocyte, Inc. (NASDAQ:ECYT) has declined 24.78% since June 2, 2016 and is downtrending. It has underperformed by 41.48% the S&P500.

Endocyte a biopharmaceutical company. The firm's market cap is $123.06 million. The Firm is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics.

Investors sentiment increased to 1.38 in Q4 2016. Its up 0.49, from 0.89 in 2016Q3. It is positive, as 7 investors sold Endocyte, Inc. shares while 22 reduced holdings. 13 funds opened positions while 27 raised stakes.

Concannon Wealth Management stated it has 0.09% in Endocyte, Inc. Nationwide Fund Advsrs reported 46,828 shares or 0% of all its holdings. Moreover, Alliancebernstein Limited Partnership has 0% invested in Endocyte, Inc. (NASDAQ:ECYT). Barclays Public Limited Com owns 8,474 shares or 0% of their USA portfolio. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.01. Rhumbline Advisers holds 0% of its portfolio in Endocyte, Inc. (NASDAQ:ECYT). Geode Ltd Liability Company holds 0% or 254,619 shares in its portfolio. Jacobs Levy Equity Mgmt Incorporated holds 0% or 76,374 shares in its portfolio.

In a research report released Friday, Cowen analyst Boris Peaker downgraded shares of Endocyte, Inc.

Endocyte (NASDAQ:ECYT) last posted its quarterly earnings results on Wednesday, May 10th. (NASDAQ:ECYT) or 10,720 shares. The institutional investor owned 806,516 shares of the biopharmaceutical company's stock after selling 15,027 shares during the period. (NASDAQ:ECYT) hit a new 52-week low and has $1.76 target or 4.00 % below today's $1.83 share price. ECYT mean recommendation is 2.00. Dean Capital Management owns 88,075 shares or 1.76% of their U.S. portfolio.

Best time to invest in stock market is when things are on odd side, and it's not easy how to pick stocks.

If we look at stock performance in last active day trading, we see that stock has moved gained 0.66% to end the day at $50.65.

D'autres rapports CampDesrEcrues

Discuter de cet article